Cost-Effectiveness Analysis of Fourth- or Further-Line Ripretinib in Advanced Gastrointestinal Stromal Tumors
Wei‐Ting Liao(Wuhan University), Qiu Li(Macau University of Science and Technology), Qiuji Wu(Wuhan University), Yang Yang(Sichuan University), Hui Luo, Huiqiong Xu(Sichuan University), Kexun Zhou(Sichuan University), Wanting Lei(Sichuan University), Mingyang Feng(Sichuan University), Feng Wen(Sichuan University), David W. Hutton(University of Michigan)
Cited by 1
Related Papers
Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses
|The Lancet|2022|407
Association of a functional variant downstream of TNFAIP3 with systemic lupus erythematosus
|Nature Genetics|2011|284
NOX2-dependent ATM kinase activation dictates pro-inflammatory macrophage phenotype and improves effectiveness to radiation therapy
|Cell Death and Differentiation|2017|75